Lexeo Therapeutics, Inc. (LXEO)
(Delayed Data from NSDQ)
$15.46 USD
-0.02 (-0.13%)
Updated May 24, 2024 04:00 PM ET
After-Market: $15.45 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
LXEO 15.46 -0.02(-0.13%)
Will LXEO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LXEO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LXEO
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
LXEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LXEO
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)
RBC Capital Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics reports Q1 results
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics reports Q1 EPS (77c), consensus (77c)